Nicox S.A.. (3/1/17). "Press Release: Nicox to Participate at Two Upcoming Investor Conferences". Sophia Antipolis.

	Region	Boston, MA
	Country	United States (USA)
	Organisation	Nicox S.A. (Euronext Paris: COX)
	Group	Nicox (Group)
	Organisation 2	Cowen & Company LLC
	Group	Cowen (Group)
	Product	Cowen & Co. Annual Health Care Conference 2017 Boston
	Product 2	Oppenheimer & Co. Annual Healthcare Conference 2017 New York
	Index term	Nicox–Cowen: investor conference, 201703 supply service Nicox presents at Cowen & Co Annual Health Care Conference 2017
	Index term 2	Nicox–Oppenheimer: investor conference, 201703 supply service Nicox presents at Oppenheimer Annual Healthcare Conference in New York
	Person	Spence, Gavin (Nicox 201607 EVP Corporate Development)
	Person 2	Perez, Julien (NewCap. 201509)

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that members of the management team will participate in the following investor conferences in March 2017 in the United States:

Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7 at 9:20 a.m. ET at the Boston Marriott Copley Place in Boston. The presentation will be available on Nicox website (www.nicox.com) in "Presentations & Events".

Oppenheimer 27th Annual Healthcare Conference on Wednesday, March 22 at 8:35 a.m. ET at the Westin Grand Central Hotel in New York. A live webcast of the presentation will be available on Nicox website (www.nicox.com) in "Presentations & Events". A replay of the webcast will be archived for 90 days following the date of the presentation.

Members of the management team will also be available for one-on-one meetings at the conferences.

About Nicox

Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com .

Analyst coverage

Bryan, Garnier & Co Hugo Solvet Paris, France
Invest Securities Martial Descoutures Paris, France
Gilbert Dupont Damien Choplain Paris, France
Stifel Olivia Manser London, UK

Upcoming financial and business conferences

April 4-5 Needham's 16th Annual Healthcare Conference New York, US
April 18-19 Small Cap Event Paris, France
May 3-4 Deutsche Bank 42nd Annual Health Care Conference Boston, US
May 22-23 BioEquity Europe Paris, France
May 30 Gilbert Dupont 15th Annual Healthcare Conference Paris, France
June 19-22 2017 BIO International Convention San Diego, US

Contacts

Nicox
Gavin Spencer,
Executive Vice President Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investor Relations
Europe
NewCap
Julien Perez, Valentine Brouchot
T +33 (0)1 44 71 94 94
nicox@newcap.eu

Media Relations

United Kingdom
Jonathan Birt
T +44 7860 361 746
jonathan.birt@ymail.com

United States
Argot Partners
Melissa Forst
T +1 (212) 600-1902
melissa@argotpartners.com

France
NewCap
Nicolas Merigeau
T +33 (0)1 44 71 94 98
nicox@newcap.eu

United States
Argot Partners
Eliza Schleifstein
T +1 (917) 763-8106
eliza@argotpartners.com

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

Record changed: 2023-06-05